Galectin Therapeutics Inc (NASDAQ:GALT)

During the Trading Day
3.37 -0.03 / -0.88%
As of 4:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
3.37 0.00 / 0.00%
 
Volume: 551.00
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$75.8M

Company Description

Galectin Therapeutics, Inc. is a development stage company, which is engaged in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Contact Information

Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
P:(678) 620-3186
Investor Relations:

Employees

Shareholders

Other institutional6.94%
Individual stakeholders10.32%
Mutual fund holders10.23%

Top Executives

Peter G. TraberPresident, CEO, Director & Chief Medical Officer
Harold H. ShlevinChief Operating Officer & Secretary
Jack W. CallicuttChief Financial Officer
Eliezer ZomerExecutive VP-Manufacturing & Product Development
Rex HortonExecutive Director-Regulatory Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account